



President Francisco X REAL
 Epithelial Carcinogenesis Group
 Molecular Pathology Programme
 Centro Nacional de Investigaciones Oncológicas
 Melchor Fernández Almagro 3
 28029-Madrid
 Spain
 Tel: +34 917 328 000

Secretary Peter HEGYI
 First Department of Medicine
 Faculty of Medicine
 University of Szeged
 8-10 Koranyi fasor
 H-6720, Szeged
 Hungary
 Tel: +36-62-545200
 Fax: +36-62-545185

Treasurer Rolf GRAF
 Department of Surgery, Div. of
 Visceral & Transplant Surgery
 University Hospital
 Rämistrasse 100
 8091 Zurich
 Switzerland
 Tel: +41-44-2552071
 Fax: +41-44-2554449

APPLICATION FORM

for General Councillor (representing Clinical Science) of the European Pancreatic Club
 (EPC)

1	Personal data	Name: Jorg Kleeff, MD Username (www.e-p-c.org): Country: Germany National Society: DPC (Deutscher Pankreasclub)
2	Membership	List of years when the applicant was member of EPC: EPC member since 2000 DPC member since 2002 IAP member since 2003 List of years when the applicant attended the annual EPC meeting: 1999 Lüneburg 2000 Kiel 2002 Heidelberg 2005 Graz 2006 Tampere 2010 Stockholm 2011 Magdeburg 2014 Southampton List of years when the applicant submitted (as first or last author) an abstract(s) for the annual EPC meeting: There were presentations from my group at all meetings listed above (plus additional meetings), plus some invited talks
3	Publications	List of the best 5 original/review papers in international journals (last 5 years): <ul style="list-style-type: none"> • Kong B, Wu W, Cheng T, Schlitter AM, Qian C, Bruns P, Jian Z, Jäger C, Regel I, Raulefs S, Behler N, Irmeler M, Beckers J, Friess H, Erkan M, Siveke JT, Tannapfel A, Hahn SA, Theis FJ, Esposito I, Kleeff J*, Michalski CW*. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. Gut. 2015 pii: gutjnl-2014-307616. doi: 10.1136/gutjnl-2014-307616. • De Oliveira T, Abiatari I, Raulefs S, Sauliunaite D, Erkan M, Kong B, Friess H, Michalski CW, Kleeff J. Syndecan-2 promotes perineural invasion and cooperates with K-ras to induce an invasive pancreatic cancer cell phenotype. Mol. Cancer 2012; 11: 19. • Samkharadze T, Erkan M, Reiser-Erkan C, Demir E, Kong B,

		<p>Ceyhan GO, Michalski CW, Esposito I, Friess H, <u>Kleeff J</u>. Pigment Epithelium-Derived Factor Increases Neuropathy and Fibrosis in Pancreatic Cancer. Am. J. Gastroenterol. 2011; 106: 968-980.</p> <ul style="list-style-type: none"> • 193. Kong B, Michalski CW, Hong X, Valkovskaya N, Rieder S, Abiatari I, Streit S, Erkan M, Esposito I, Friess H, <u>Kleeff J</u>. AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGFbeta-mediated ERK signaling. Oncogene 2010; 29: 5146-5158. • Gillen S, Schuster T, Meyer zum Büschenfelde C, Friess H, <u>Kleeff J</u>. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Medicine 2010; 7(4): e1000267.
4	Previous positions at EPC or UEG	<p>Abstract Selection Scientific Committee member of the European Pancreatic Club EPC (2009-2011)</p> <p>Member of the Organizing team of the EPC 2002 (Heidelberg)</p>

The applicant confirms that she/he

- has read the Open call for Council Member position and fully accept its content
- has adequate time resources for volunteer work
- has good command of spoken and written English
- is available for two council meetings per year for 3 years


Name: Jorg Kleeff, MD

Date: May 18, 2015

CURRICULUM VITAE

Name: Jorg Kleeff, MD
Academic title: Prof. Dr. med.
Date and place of birth: 29.07.1969 in Erkelenz, Germany
Nationality: German

Office address: Department of Surgery
Technical University Munich
Ismaninger Strasse 22
81675 Munich, Germany
Phone: + 49 89 41 40 50 98
Fax: + 49 89 41 40 48 70
E-mail: kleeff@tum.de

Present position: Vice-Chairman, Department of Surgery, Klinikum rechts der Isar, Technical University Munich

University:

2010 Professorship, Technische Universität München
2005 Habilitation, Mechanismen der Aggressivität des Pankreaskarzinoms auf molekularer Ebene – der TGF-beta Signalweg, Ruprecht-Karls-Universität Heidelberg
1993-1995 Dissertation, Diagnostische Methoden und Epidemiologie von HTLV-I/II in Deutschland Max-von-Pettenkofer Institut, München (Prof. Dr. Klaus von der Helm)
1992-1996 Study of medicine, Ludwig-Maximilians-University Munich, Third state examination
1990-1992 Study of medicine, Eberhard-Karls-University Tübingen, Basic medical examination „Physikum“

Professional and scientific training:

10/2010 - present Vice-chairman: Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technical University Munich (Prof. Dr. Helmut Friess)
01/2009 - 09/2010 Senior attending: Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Technical University Munich (Prof. Dr. Helmut Friess)
07/2007 - 12/2008 Attending: Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar Technical University Munich (Prof. Dr. Helmut Friess)
09/2005 - 06/2007 Attending: Abteilung Allgemein-, Viszeral- und Unfallchirurgie University Heidelberg (Prof. Dr. Markus W. Buechler)
10/2001 - 08/2005 Resident: Abteilung Allgemein-, Viszeral- und Unfallchirurgie University Heidelberg (Prof. Dr. Markus W. Buechler)
03/1999 - 09/2001 Resident: Klinik für Viszerale und Transplantations-Chirurgie Inselspital, University Bern, Switzerland (Prof. Dr. Markus W. Buechler)
02/1997 - 02/1999 Postdoctoral researcher:
University of California, Irvine, USA (Prof. Dr. Murray Korc)

Research interests:

Clinical Activities: Surgical Oncology, HPB-Surgery, Colorectal Surgery

Research Activities: *Pancreatic carcinogenesis; inflammation*

- molecular and pathological analysis of pancreatic ductal adenocarcinoma
- characterization of genetic alterations, gene signatures and epigenetic networks
- analysis of KRAS, CDKN2A, TP53, BRCA2 and SMAD4/DPC4 mutations
- role of the tumor microenvironment and tumor-stroma interactions
- defining chemoresistance marker
- classification of metastatic phenotypes
- preclinical studies

Publications: Number of original peer-reviewed publications: 250; H-Index: 54

Publication List (most important publications of the last 5 years)

- Gillen S, Schuster T, Meyer zum Büschenfelde C, Friess H, **Kleeff J**. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. *PLoS Medicine* 2010; 7(4): e1000267.
- Erkan M, Weis N, Pan Z, Schwager C, Samkharadze T, Jiang X, Wirkner U, Giese NA, Ansorge W, Debus J, Huber PE, Friess H, Abdollahi A, **Kleeff J**. Organ-, Inflammation- and Cancer Specific Transcriptional Fingerprints of Pancreatic and Hepatic Stellate Cells. *Mol. Cancer* 2010; 9: 88.
- Kong B, Michalski CW, Hong X, Valkovskaya N, Rieder S, Abiatari I, Streit S, Erkan M, Esposito I, Friess H, **Kleeff J**. AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGFbeta-mediated ERK signaling. *Oncogene* 2010; 29: 5146-5158.
- Samkharadze T, Erkan M, Reiser-Erkan C, Demir E, Kong B, Ceyhan GO, Michalski CW, Esposito I, Friess H, **Kleeff J**. Pigment Epithelium-Derived Factor Increases Neuropathy and Fibrosis in Pancreatic Cancer. *Am. J. Gastroenterol.* 2011; 106: 968-980.
- Erkan M, Adler G, Apte MV, Bachem MG, Buchholz M, Detlefsen S, Esposito I, Friess H, Gress TM, Habisch HJ, Hwang RF, Jaster R, **Kleeff J**, Klöppel G, Kordes C, Logsdon CD, Masamune A, Michalski CW, Oh J, Phillips PA, Pinzani M, Reiser-Erkan C, Tsukamoto H, Wilson J. StellaTUM: current consensus and discussion on pancreatic stellate cell research. *Gut.* 2012; 61: 172-178.
- De Oliveira T, Abiatari I, Raulefs S, Sauliunaite D, Erkan M, Kong B, Friess H, Michalski CW, **Kleeff J**. Syndecan-2 promotes perineural invasion and cooperates with K-ras to induce an invasive pancreatic cancer cell phenotype. *Mol. Cancer* 2012; 11: 19.
- Li N, Wu X, Holzer RG, Lee JH, Todoric J, Park EJ, Ogata H, Gukovskaya AS, Gukovsky I, Pizzo DP, Vandenberg S, Tarin D, Atay C, Arkan MC, Deerinck TJ, Moscat J, Diaz-Meco M, Dawson D, Erkan M, **Kleeff J**, Karin M. Loss of acinar cell IKK α triggers spontaneous pancreatitis in mice. *J. Clin. Invest.* 2013; 123: 2231-2243.
- Stellwag T, Michalski CW, Kong B, Erkan M, Reiser-Erkan C, Jäger C, Meinel C, Friess H, **Kleeff J**. Comparative analysis of the revenues of pylorus-preserving pancreatic head resections and laparoscopic cholecystectomies as prototypic surgical procedures in the German health-care system. *Langenbecks Arch Surg.* 2013; 398: 825-831.
- Balic A, Dræby Sørensen M, Trabulo SM, Sainz B Jr, Cioffi M, Vieira CR, Miranda-Lorenzo I, Hidalgo M, **Kleeff J**, Erkan M, Heeschen C. Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. *Mol Cancer Ther.* 2014; 13: 1758-1771.

- Miranda-Lorenzo I, Dorado J, Lonardo E, Alcalá S, Serrano AG, Clausell-Tormos J, Cioffi M, Megias D, Zagorac S, Balic A, Hidalgo M, Erkan M, **Kleeff J**, Scarpa A, Sainz B Jr, Heeschen C. Intracellular autofluorescence: a biomarker for epithelial cancer stem cells. *Nat Methods*. 2014; 11: 1161-1169.
- Nitsche U, Müller TC, Späth C, Cresswell L, Wilhelm D, Friess H, Michalski CW, **Kleeff J**. The evidence based dilemma of intraperitoneal drainage for pancreatic resection - a systematic review and meta-analysis. *BMC Surg*. 2014; 14(1): 76.
- Mihaljevic AL, Schirren R, Ozer M, Ottl S, Grün S, Michalski CW, Erkan M, Jäger C, Reiser-Erkan C, Kehl V, Schuster T, Roder J, Clauer U, Orlitsch C, Hoffmann TF, Lange R, Harzenetter T, Steiner P, Michalski M, Henkel K, Stadler J, Pistorius GA, Jahn A, Obermaier R, Unger R, Strunk R, Willeke F, Vogelsang H, Halve B, Dietl KH, Hilgenstock H, Meyer A, Krämling HJ, Wagner M, Schoenberg MH, Zeller F, Schmidt J, Friess H, **Kleeff J**. Multicenter Double-Blinded Randomized Controlled Trial of Standard Abdominal Wound Edge Protection With Surgical Dressings Versus Coverage With a Sterile Circular Polyethylene Drape for Prevention of Surgical Site Infections: A CHIR-Net Trial (BaFO; NCT01181206). *Ann Surg*. 2014; 260: 730-739.
- Berchtold S, Grünwald B, Krüger A, Reithmeier A, Hähl T, Cheng T, Feuchtinger A, Born D, Erkan M, **Kleeff J**, Esposito I. Collagen type V promotes the malignant phenotype of pancreatic ductal adenocarcinoma. *Cancer Lett*. 2015; 356: 721-732.
- Kong B, Wu W, Cheng T, Schlitter AM, Qian C, Bruns P, Jian Z, Jäger C, Regel I, Raulefs S, Behler N, Irmeler M, Beckers J, Friess H, Erkan M, Siveke JT, Tannapfel A, Hahn SA, Theis FJ, Esposito I, **Kleeff J**, Michalski CW. A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling. *Gut*. 2015; doi: 10.1136/gutjnl-2014-307616.
- Kong B, Wu W, Valkovska N, Jäger C, Hong X, Nitsche U, Friess H, Esposito I, Erkan M, **Kleeff J**, Michalski CW. A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels. *Sci Rep*. 2015 Feb 6;5:8109. doi: 10.1038/srep08109.
- Kong B, Wang W, Esposito I, Friess H, Michalski CW, Kleeff J. Increased expression of Nodal correlates with reduced patient survival in pancreatic cancer. *Pancreatology*. 2015 doi: 10.1016/j.pan.2015.02.001.
- Cioffi M, Trabulo SM, Hidalgo M, Costello E, Greenhalf W, Erkan M, **Kleeff J**, Sainz B Jr, Heeschen C. Inhibition of CD47 effectively targets pancreatic cancer stem cells via dual mechanism. *Clin Cancer Res*. 2015; 15;21(10):2325-2337.